Tag:

AstraZeneca

Latest Headlines

Latest Headlines

AstraZeneca and Singapore's A*STAR ink research pact on complex heart failure syndrome

U.K.-based drugmaker AstraZeneca said it supports research into new therapies for heart failure with preserved ejection fraction, a complex syndrome for which there is currently no effective treatment for patients, by working with Singaporean research and clinical communities in a two-year program.

AstraZeneca adds hefty share grant to CEO's £3.5M pay

AstraZeneca CEO Pascal Soriot got a bit of a pay raise last year, with a 3% bump to his base salary. His bonus jumped, too, putting his salary, bonus and cash benefits at £3.5 million. But Soriot's real boost came in the form of equity that won't pay off for a few years: Some £4.8 million in shares, under the company's long-term incentive plan.

AstraZeneca's rapid-fire IT dealmaking continues with Elixir hookup

AstraZeneca is extending its use of Elixir Software's R&D workflow-management software, in part to support communication while it is moving its focal point in the United Kingdom from Alderley Park to Cambridge.

The PD-1 wave? Report says it's a $33B tsunami, with BMS surfing for first place

There's a reason immuno-oncology is among the hottest fields in biopharma today--and that's the $20 billion or so in 2022 sales that many analysts estimate. No wonder Bristol-Myers Squibb, Merck, AstraZeneca and Roche are speeding ahead with their research in the field, with Sanofi, Novartis and Pfizer racing to catch up.

AstraZeneca director pushing to tie exec pay to big growth promises

The promises are coming home to roost for AstraZeneca CEO Pascal Soriot. Or so reports The Sunday Times, which says the U.K.-based company is once again under pressure to put Soriot's bonus pay on the line for the big goals he touted in defending against Pfizer's $100 billion takeover bid last year.

Exclusive: AstraZeneca spinning out its anti-infectives R&D unit in Waltham

Pushing through on a plan to get out of the early-stage anti-infectives R&D space, AstraZeneca is spinning out its Waltham, MA-based company into an independent biotech, a move that will have an impact on the 95 staffers remaining in the swiftly dwindling operation.

From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets (Part 2)

Here is part two of comments from C-suite execs on emerging markets and Asia in the latest quarterly conference calls.

Actavis wins FDA approval for a new 'superbug' antibiotic

Actavis won the FDA's blessing for a new combination antibiotic treatment targeting drug-resistant infections, setting the stage for a showdown with Merck and its $9.5 billion splash into the field.

AstraZeneca bets $122.5M on oral autoimmune drugs

AstraZeneca is out to get some more shots on goal in immunology, pairing up with a nascent biotech in hopes of developing oral medicines for psoriasis, arthritis and other diseases.

AstraZeneca picks Labguru to improve collaborations with academia

AstraZeneca has struck a deal with BioData to use Labguru across its preclinical R&D sites. The deal will see AstraZeneca phase out its current patchwork of legacy systems in favor of BioData's web-based lab management system.